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ABSTRACT
OBJECTIVES
To estimate the association between the duration and 
level of exposure to different classes of anticholinergic 
drugs and subsequent incident dementia.
DESIGN
Case-control study.
SETTING
General practices in the UK contributing to the Clinical 
Practice Research Datalink.
PARTICIPANTS
40 770 patients aged 65-99 with a diagnosis of 
dementia between April 2006 and July 2015, and 
283 933 controls without dementia.
INTERVENTIONS
Daily defined doses of anticholinergic drugs coded 
using the Anticholinergic Cognitive Burden (ACB) 
scale, in total and grouped by subclass, prescribed 
4-20 years before a diagnosis of dementia.
MAIN OUTCOME MEASURES
Odds ratios for incident dementia, adjusted for a 
range of demographic and health related covariates.
RESULTS
14 453 (35%) cases and 86 403 (30%) controls were 
prescribed at least one anticholinergic drug with an 
ACB score of 3 (definite anticholinergic activity) during 
the exposure period. The adjusted odds ratio for any 
anticholinergic drug with an ACB score of 3 was 1.11 
(95% confidence interval 1.08 to 1.14). Dementia was 
associated with an increasing average ACB score. When 
considered by drug class, gastrointestinal drugs with an 
ACB score of 3 were not distinctively linked to dementia. 
The risk of dementia increased with greater exposure 
for antidepressant, urological, and antiparkinson drugs 
with an ACB score of 3. This result was also observed for 
exposure 15-20 years before a diagnosis.
CONCLUSIONS
A robust association between some classes of 
anticholinergic drugs and future dementia incidence 
was observed. This could be caused by a class 
specific effect, or by drugs being used for very early 
symptoms of dementia. Future research should 
examine anticholinergic drug classes as opposed to 
anticholinergic effects intrinsically or summing scales 
for anticholinergic exposure.
TRIAL REGISTRATION
Registered to the European Union electronic Register 
of Post-Authorisation Studies EUPAS8705.
Introduction
Dementia is a leading cause of disability and 
death,1 and its prevention is a global public health 
priority. Dementia is caused by a number of different 
neurodegenerative processes that contribute to 
irreversible cognitive decline and associated symptoms, 
such as the progressive loss of independence and daily 
functioning. Mixed dementias are more prevalent than 
is often recognised, with symptoms often more closely 
linked to overall pathological burden as opposed to 
any specific disease process.2 3 No disease modifying 
treatments for dementia exist, however, age specific 
dementia incidence across populations is declining, 
suggesting that changing lifestyles or environment 
may lead to a meaningful change in the prevalence 
of dementia.4 Hence identifying and reducing the 
exposure to risk factors that can affect any aspect of 
long term brain health is important for dementia 
prevention and cognitive health in the population.5
Middle aged and older populations are increasingly 
taking multiple drugs,6 7 but the potential adverse 
events of long term use are not well understood. 
Anticholinergic drugs block the neurotransmitter 
acetylcholine in the central or peripheral nervous 
system, and have diverse actions depending on the site. 
Anticholinergic drugs are indicated for depression, 
gastrointestinal disorders, Parkinson’s disease, urinary 
incontinence, epilepsy, and to manage allergies. It is 
well known that anticholinergics affect cognition,8 
and guidelines suggest they are to be avoided among 
frail older people.9 Use of anticholinergic drugs among 
people with dementia is recognised as inappropriate 
by both the Beers and the Screening Tool of Older 
Persons’ potentially inappropriate Prescriptions 
(STOPP) criteria.10 11 Over the past decade, prolonged 
exposure to anticholinergic drugs has been linked to 
long term cognitive decline or dementia incidence 
among community living cohorts and nursing home 
residents.12-17 However, these studies have been 
limited in their ability to determine if the increased 
risk is specific to the anticholinergic action itself, and 
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WhAT IS AlReAdy knoWn on ThIS TopIC
Use of drugs with anticholinergic activity is associated with impaired cognition 
in the short term
It is not known if the reported associations between the use of anticholinergic 
drugs and future cognitive decline and dementia incidence can be attributed to 
anticholinergic activity
WhAT ThIS STudy AddS
Antidepressant, urological, and antiparkinson drugs with definite anticholinergic 
activity are linked to future dementia incidence, with associations persisting up 
to 20 years after exposure
Gastrointestinal and cardiovascular anticholinergic drugs are not positively 
associated with later dementia incidence
There is no evidence for a cumulative harm of drugs considered possibly 
anticholinergic
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whether or not the association is owing to the drugs 
or the underlying conditions for which they were 
prescribed. In particular, late life depression is thought 
to be an early symptom of dementia,18 19 whereas 
studies of whether midlife depression is a risk factor 
for later life dementia have had mixed findings.20 21
We present a nested case-control study using the UK’s 
Clinical Practice Research Datalink (CPRD), in which 
we select patients with a new diagnosis of dementia, 
and compare their prescriptions of anticholinergic 
drugs 4-20 years before a diagnosis of dementia with 
that of a matched group of control patients without 
dementia. We had three objectives. Firstly, to estimate 
the association between chronic anticholinergic drug 
use and future dementia incidence while controlling 
for potential confounders. Secondly, to explore 
whether any observed effect was specific to a particular 
drug class. Thirdly, to test how the association varied 
with the time to dementia incidence and amount of 
exposure within each class.
Methods
Study design
We performed a nested case-control study using 
data from the Clinical Practice Research Datalink 
(CPRD), which includes anonymised diagnosis, 
referral, and prescribing records for more than 11.3 
million patients from 674 primary care practices in 
the UK. CPRD data are broadly representative of the 
UK population in terms of sex, age, and ethnicity.22 
All coded information in the primary care record for 
each selected patient is available to researchers. This 
includes demographic detail, lifestyle information, 
any diagnoses and symptoms recorded by the general 
practitioner, referrals to other healthcare services 
and subsequent findings, and treatments initiated 
or continued in primary care. In the UK, a patient’s 
registered primary care practice is the coordinator of 
most of their healthcare, and acts as the main gateway 
for access to secondary care. Hence most of a patient’s 
healthcare information is held in their primary care 
record. Secondary care episodes or privately obtained 
healthcare may not always be communicated to the 
patient’s registered primary care practice. An up to 
standard (UTS) date is assigned to a CPRD practice 
when the data recorded by the practice are of an 
acceptable research standard. Records of therapies 
and diagnoses made before the UTS date are available, 
but may be incomplete. 
Selection of cases and controls
Patients aged 65-99 with a recorded diagnosis of 
dementia made between April 2006 and July 2015 
were eligible to be selected as cases. We also required 
at least six years of UTS data before a diagnosis 
to allow for a four year delay before a diagnosis of 
dementia, at least a one year drug exposure period 
(DEP), and to ascertain covariates, we required data 
for one year before the DEP. A diagnosis of dementia 
was defined as the presence in the patient’s record of 
any Read codes for dementia as a diagnosis, symptom, 
or referral, or prescription for a cognitive enhancer 
(memantine, donepezil, rivastigmine, galantamine, 
or tacrine) if a code for a diagnosis of dementia was 
recorded within 12 months. Dementia codes were 
derived by comparing a previous published list with 
the Department of Health’s Quality and Outcomes 
Framework list of business codes for dementia.23 24 
These two code lists overlapped almost completely. 
The combined list was reviewed by our clinical team, 
and all codes were included in our final definition—
except those that related explicitly to alcohol related 
dementia (see supplementary materials, appendix 1 
for a full list). Cases were excluded if they had been 
diagnosed with motor neurone disease, HIV or AIDS, 
multiple sclerosis, Down’s syndrome, or alcohol abuse 
before diagnosis of dementia.
Using the diagnosis of dementia date as the index 
date, each case was matched to a maximum of seven 
controls not having been diagnosed with dementia 
before the index date. Cases and controls were 
matched on sex, year of birth (within three years), 
years of UTS data history, and area level deprivation 
measured by the index of multiple deprivation quintile 
of each practice based on its postcode.25 We used 
incidence density sampling to select controls, hence 
cases were eligible to be selected as controls for other 
cases with earlier index dates.26 Seven controls were 
used to maximise the power to detect associations 
with potentially rare exposures or covariates, and to 
adhere to the limits of the data provider regarding the 
maximum sample size for a single study.
Patients were excluded if their date of diagnosis 
of dementia was ambiguous. That is, if dementia 
annual review, history of dementia, assessment of 
psychotic and behavioural symptoms of dementia, or 
antipsychotic drug therapy for dementia was recorded 
before the index date.
Anticholinergic drugs exposure
A DEP was defined for each case-control group, 
starting at least one year after the UTS date and ending 
four years before the index date. The start and end 
dates of the DEP were identical within sets of cases 
and controls. We excluded exposures in the four 
years before the index date to avoid protopathic bias, 
whereby the drug is given for a sign or symptom of 
dementia before a diagnosis of dementia.27
Estimating the anticholinergic effect of individual 
drugs on the human brain is difficult. Serum 
anticholinergic activity measured by a receptor 
bioassay does not correlate well with effects on 
cognition,16 28 and so the anticholinergic effects of 
drugs are usually classified using scales developed by 
expert consensus aided by a literature review.29 In this 
study, all drugs prescribed to each patient during the 
DEP were classified according to the 2012 update of the 
Anticholinergic Cognitive Burden (ACB) scale.30 Drugs 
with serum anticholinergic activity or in vitro affinity 
to muscarinic receptors, but with no known clinically 
relevant negative cognitive effects are assigned a score 
of 1 (possibly anticholinergic). Drugs with established 
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and clinically relevant anticholinergic effects are 
assigned a score of 2 based on blood-brain penetration 
(definitely anticholinergic). Drugs with a score of 2 
that also have reported associations with delirium are 
assigned a score of 3 (definitely anticholinergic). All 
other drugs are assigned a score of 0. For the drugs 
available in the UK in the last 30 years without an ACB 
score, we made the following assumptions: thiazide 
diuretics, loop diuretics, and antihistamines have an 
ACB score of 1; tricyclic antidepressants have an ACB 
score of 3; and creams, eye drops, and ear drops have 
an ACB score of 0.
Our primary exposures were the number of defined 
daily doses (DDDs) prescribed for drugs within a 
drug class for each ACB score during the DEP. The 
DDD is defined as the assumed average maintenance 
daily dose for a drug based on its main indication in 
adults, using the DDD values assigned by the World 
Health Organisation’s (WHO) Collaborating Centre 
for Drug Statistics Methodology. For prescriptions of 
different drugs with the same ACB score, DDDs were 
summed. We then categorised exposure during the 
DEP as 0, 1-13, 14-89, 90-364, 365-1459, or more 
than 1460 DDDs.
We further categorised the drugs with anticholinergic 
properties as either analgesic (WHO Anatomical 
Therapeutic Chemical code N02), antidepressant 
(N06A), antipsychotic (N05A), cardiovascular (C), 
gastrointestinal (A), antiparkinson (N04), respiratory 
(R), urological (G04), or other. These categories 
separate the main indications for anticholinergic 
drugs and correlate closely with their pharmacological 
action. Drugs in these classes have similar receptor 
bindings.
Finally, an average ACB score was calculated as the 
average across the DEP of the sum of the ACB score 
for each drug being used at any given time. This was 
then categorised into groups reflecting approximate 
quintiles of the sample, but with two additional groups 
representing those with particularly high (3-5 and 5 or 
more) average ACB scores.
Covariates
We considered potential confounders to be any 
variable suspected to be linked to dementia incidence 
or an indication for any of the drugs examined. A full 
list of covariates and their definitions are available (see 
supplementary materials, appendix 2). In summary, 
we included diagnoses of cardiovascular disease, other 
dementia risk factors and correlates, other indications 
for anticholinergics, other drug use, sociodemographic 
variables, and records of health related lifestyle 
information where available.
Exposures could occur at any time during an 
individual’s DEP and so, as with many case-control 
studies,31 it is not clear at what point we should 
determine the presence or absence of confounding 
factors. Our primary analysis measured confounders 
recorded up to the end of the DEP to best capture the 
indications of the drugs. We also coded the status 
of each patient with respect to each covariate up 
to the start of the DEP, as some variables could be 
consequences of drug exposure.
Statistical analysis
Patterns of exposures and covariates were described 
for case and control groups separately.
Primary analysis compared the number of DDDs 
of drugs with an ACB score of 1, 2, or 3 prescribed to 
cases and controls during the DEP, controlling for 
covariates recorded at the end of each DEP. We used 
multiple conditional logistic regression to estimate 
the independent association between classes of 
anticholinergic prescriptions and a diagnosis of 
dementia, adjusting for all other anticholinergic 
classes and covariates described previously. Adjusted 
odds ratios are reported with 95% confidence intervals, 
however, P<0.01 was prespecified as a threshold for 
statistical significance owing to the large number of 
subgroups being examined. All analysis was conducted 
with Stata version 14 (StataCorp, College Station, TX).
Secondary prespecified analyses included: 
disaggregation of exposure by drug class; testing the 
effect of exposure 4-10, 10-15, and 15-20 years before 
the index date in those with 6 or more, 11 or more, and 
16 or more years of UTS data history respectively; and 
testing the effect of the average ACB score over the DEP.
Sensitivity analyses included repeating our primary 
analysis three times. Firstly, to adjust for covariates 
measured up to the start rather than the end of the 
DEP, and the following post hoc analyses. Secondly, 
to emulate a new user design by excluding patients 
prescribed medications with an ACB score of 2 or 3 
in the 12 months before the DEP.32 Thirdly, to recode 
binary exposure variables to correspond to 90 or more 
DDDs prescribed instead of any prescription during 
the DEP, to represent longer term rather than one-off 
exposure.
To test the likely impact of missing lifestyle covariate 
data, we compared findings with and without 
adjustment for these lifestyle variables in complete 
data and in the full dataset using a missing category 
for each variable. As with other analyses of routine 
data, diagnosed health conditions or other drugs are 
assumed absent if there is no mention in the primary 
care record. Deprivation is based on practice location 
and so is known for all patients.
For a final prespecified sensitivity analysis, we 
recoded drugs by using the Anticholinergic Drug 
Scale (ADS) instead of the ACB scale. ADS classifies 
the degree of anticholinergic activity of each drugs 
on a scale from 0 (no anticholinergic effect) to 3 
(marked anticholinergic effect) in accordance with 
a literature review and expert consensus.33 Sample 
size was determined by the maximum available data 
within CPRD.
Patient involvement
Four Alzheimer’s Society Research Network Volunteers 
acted as study monitors and service user representatives 
on our study steering committee. These individuals 
have all acted as carers of people with dementia. The 
RESEARCH
4 doi: 10.1136/bmj.k1315 | BMJ 2018;361:k1315 | the bmj
monitors contributed to our protocol development by 
sharing their experiences of psychoactive drug use and 
their view of the balance between the benefits of drug 
use and potential cognitive decline. Monitors met the 
study team to discuss study progress every six months. 
They are assisting us with the dissemination of our 
study, making sure that lay summaries of results are 
accessible and easily understood.
Results
The source population consisted of 66 136 patients 
with a diagnosis of dementia between April 2006 and 
July 2015. After applying the exclusion criteria, our 
analysis included 40 770 cases and 283 933 controls, 
with the majority of cases being matched to seven 
controls (see supplementary materials, figure 1). Most 
patients (n=254 083, 78%) were from general practices 
in England, with 30 817 (9%) from Scotland, 29 575 
(9%) from Wales, and 10 228 (3%) from Northern 
Ireland. The median age of patients at index date was 
83 (interquartile range 78-87) and 63% were female. 
The median drug exposure period (DEP) was 7.1 years 
(interquartile range 4.0-11.3, range 1-16). Table 1 
shows that diagnoses of conditions related to dementia 
and indications for anticholinergics increased during 
the DEP. As an example, the proportion of dementia 
cases diagnosed with depression at the start of the DEP 
was 12% (n=5071), rising to 20% (n=8030) during the 
DEP. Information on smoking status, harmful alcohol 
use, and body mass index becomes more complete by 
the end of the DEP. As expected, the average body mass 
index decreases during the DEP for dementia cases, 
but increases for the control group.
Frequency of anticholinergic drugs use
During the DEP, 14 453 (35%) cases and 86 403 (30%) 
controls were prescribed at least one anticholinergic 
drug with an Anticholinergic Cognitive Burden (ACB) 
score of 3. A total of 1 793 505 prescriptions for 
drugs with an ACB score of 3 were written during the 
DEP. The five most common drugs were amitriptyline 
(29%), dosulepin (also known as dothiepin; 16%), 
paroxetine (8%), oxybutynin (7%), and tolterodine 
(7%). Only 1429 (3.5%) cases and 7909 (2.8%) 
controls were prescribed drugs with an ACB score of 
2, with carbamazepine accounting for 87% of these 
prescriptions. Most patients (89% of cases and 87% 
of controls) received at least one prescription for a 
drug with an ACB score of 1 during the DEP, with 
cardiovascular drugs accounting for 63% of these 
prescriptions. The number of prescriptions for each 
ACB score is further described in supplementary 
materials, table 1.
Primary analysis
Table 2 shows that there was a positive and significant 
association between the prescription of any drug 
with an ACB score of 1, 2, or 3 and dementia with 
corresponding odds ratios of 1.10 (95% confidence 
interval 1.06 to 1.15), 1.10 (1.03 to 1.16), and 
1.11 (1.08 to 1.14). These values were adjusted for 
covariates measured at the end of the DEP. A dose-
response effect was evident for prescribed doses of 
drugs with an ACB score of 2 or 3. However, there was 
no dose-response effect for drugs with an ACB score of 
1. Table 2 shows that an odds ratio of approximately 
1.1 was seen for those prescribed drugs with an ACB 
score of 1, regardless of the number prescribed, 
including those with less than 14 DDD exposure. The 
associations are attenuated from the crude rates when 
adjusting for drug use at the start of the DEP, and 
are further reduced only slightly when adjusting for 
covariates at the end of the DEP.
There was a dose-response effect linking average 
anticholinergic load, measured by the average ACB 
score over the DEP, with dementia incidence, although 
this is only evident for those with an average score of 3 
or more (table 2).
Exposure by drug class
Table 3 shows that, when analysed by class, there was 
a significant association between dementia incidence 
and any prescription of antidepressant, antiparkinson, 
or urological drugs with an ACB score of 3, but no 
association with antispasmodic, antipsychotic, 
antihistamine, or other drugs with an ACB score of 3. 
Prescriptions for drugs with an ACB score of 2 were 
relatively rare, and so results are imprecise in this 
group, but there is some evidence for an association 
between dementia incidence and prescription of 
antiparkinson drugs. We found positive associations 
for antidepressant drugs with an ACB score of 1 with 
an increased risk of dementia, but not with any other 
drugs with an ACB score of 1. Supplementary materials 
table 2 shows the associations between dementia 
incidence and the number of DDDs by drug class. 
These associations are consistent with the findings in 
table 3, except that a tentative effect of antihistamines 
with an ACB score of 3 is seen for patients with more 
than 365 DDDs prescribed during the DEP. Use of 
gastrointestinal drugs with an ACB score of 1 or 3, 
and cardiovascular drugs with an ACB score of 1 
was associated with a minor reduction in the risk of 
dementia.
Exposure by time before a diagnosis of dementia
Table 4 shows the effect of exposure in three different 
periods (4-10, 10-15, and 15-20 years) before the 
index date. Associations with prescriptions for drugs 
with an ACB score of 3 were consistent across the 
DEP. Associations with prescriptions for drugs with 
an ACB score of 1 and 2 were more apparent closer 
to the index date. In particular, the prescription of 
any drug with an ACB score of 3 15-20 years before 
a diagnosis of dementia was significantly associated 
with greater dementia incidence with an odds ratio of 
1.17 (95% confidence interval 1.10 to 1.24) adjusted 
for covariates at the start of the DEP. Prescriptions 
at 15-20 years before a diagnosis of dementia for 
antidepressant and urological drugs with an ACB score 
of 3 remained consistently significantly associated with 
dementia incidence with odds ratios of 1.19 (1.10 to 
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Table 1 | Characteristics of 40 770 case patients with a diagnosis of dementia and 283 933 controls from the Clinical 
Practice Research Datalink at the start and end of the drug exposure period (DEP). Values are numbers (percentages) 
unless stated otherwise
Characteristic
Start End
Cases Controls Cases Controls 
Lifestyle
Current smoker* 5058 (12.4) 34 652 (12.2) 4516 (11.1) 30 976 (10.9)
Harmful alcohol use† 166 (0.4) 980 (0.3) 377 (0.9) 2316 (0.8)
Mean (SD) body mass index‡ 26.4 (6.3) 26.5 (6.9) 26.1 (5.2) 26.8 (5.6)
Cardiovascular or cerebrovascular and related diagnoses
Diabetes 2734 (6.7) 16 362 (5.8) 5392 (13.2) 34 015 (12.0)
Diabetes complications 418 (1.0) 2206 (0.8) 1378 (3.4) 7678 (2.7)
Hyperlipidemia 2740 (6.7) 16 369 (5.8) 6481 (15.9) 40 796 (14.4)
Hypertension 13 328 (32.7) 91 737 (32.3) 22 104 (54.2) 155 262 (54.7)
Stroke or transient ischaemic attack 1969 (4.8) 11 734 (4.1) 4747 (11.6) 25 856 (9.1)
Congestive heart disease 5279 (12.9) 33947 (12) 8388 (20.6) 54 615 (19.2)
Heart failure 819 (2.0) 5921 (2.1) 2140 (5.2) 15 961 (5.6)
Peripheral arterial disease 897 (2.2) 5953 (2.1) 2110 (5.2) 13 818 (4.9)
Atrial fibrillation 1303 (3.2) 8856 (3.1) 3744 (9.2) 24 591 (8.7)
Angina 3704 (9.1) 23 213 (8.2) 6006 (14.7) 38 602 (13.6)
Myocardial infarction 1820 (4.5) 12 051 (4.2) 2908 (7.1) 19 602 (6.9)
Coronary artery operations 831 (2.0) 5261 (1.9) 1711 (4.2) 11 002 (3.9)
Deep vein thrombosis 552 (1.4) 4172 (1.5) 1110 (2.7) 8101 (2.9)
Mental health diagnoses
Depression 5071 (12.4) 29 676 (10.5) 8030 (19.7) 44 264 (15.6)
Severe depression 400 (1.0) 2175 (0.8) 804 (2.0) 4056 (1.4)
Depression symptoms 1393 (3.4) 7880 (2.8) 4577 (11.2) 24 220 (8.5)
Mean (SD) depression duration (years)§ 13.8 (12.8) 14.2 (12.8) 14.3 (13.0) 15.2 (13.2)
Severe mental illness 294 (0.7) 1558 (0.5) 431 (1.1) 2078 (0.7)
Anxiety 3641 (8.9) 22 229 (7.8) 6190 (15.2) 35 598 (12.5)
Anxiety symptoms 1172 (2.9) 6457 (2.3) 3763 (9.2) 20 366 (7.2)
Other diagnoses
Parkinson’s disease 237 (0.6) 958 (0.3) 1448 (3.6) 4283 (1.5)
Epilepsy 542 (1.3) 2799 (1.0) 771 (1.9) 3860 (1.4)
Insomnia 2940 (7.2) 18 407 (6.5) 7351 (18.0) 45 227 (15.9)
Fatigue 2666 (6.5) 15 825 (5.6) 8561 (21.0) 50 351 (17.7)
Other sleep problems 583 (1.4) 3501 (1.2) 2772 (6.8) 15 878 (5.6)
Hemiplegia and paraplegia 131 (0.3) 816 (0.3) 235 (0.6) 1406 (0.5)
Drug abuse 297 (0.7) 1694 (0.6) 414 (1.0) 2357 (0.8)
Migraine 1320 (3.2) 8625 (3.0) 1839 (4.5) 11 999 (4.2)
Headache 2540 (6.2) 15 653 (5.5) 6102 (15) 37 602 (13.2)
Back or neck pain 12 225 (30.0) 79 108 (27.9) 21 123 (51.8) 138 554 (48.8)
Neuropathy 750 (1.8) 4766 (1.7) 2030 (5.0) 13 098 (4.6)
Meniere’s disease 340 (0.8) 2353 (0.8) 471 (1.2) 3397 (1.2)
Restless leg syndrome 169 (0.4) 1088 (0.4) 610 (1.5) 3955 (1.4)
Chronic obstructive pulmonary disease 899 (2.2) 6327 (2.2) 2534 (6.2) 18 012 (6.3)
Asthma 3134 (7.7) 20 991 (7.4) 4375 (10.7) 29 822 (10.5)
Rhinitis 2556 (6.3) 16 617 (5.9) 5155 (12.6) 32 956 (11.6)
Gastroesophageal reflux disease or oesophagitis 2876 (7.1) 18 277 (6.4) 6141 (15.1) 39 437 (13.9)
Peptic or gastric ulcer 1122 (2.8) 6779 (2.4) 2530 (6.2) 15 724 (5.5)
Irritable bowel syndrome 210 (0.5) 1316 (0.5) 2328 (5.7) 15 277 (5.4)
Inflammatory bowel disease 1087 (2.7) 6692 (2.4) 2451 (6.0) 15 523 (5.5)
Intestinal surgery, colostomy, or ileostomy 1438 (3.5) 9515 (3.4) 3137 (7.7) 20 215 (7.1)
Liver disease 93 (0.2) 650 (0.2) 207 (0.6) 1312 (0.5)
Osteoarthritis 7925 (19.4) 50 644 (17.8) 14 627 (35.9) 94 681 (33.3)
Rheumatoid arthritis 486 (1.2) 3700 (1.3) 806 (2.0) 5799 (2.0)
Dermatitis 6986 (17.1) 45 613 (16.1) 13 364 (32.8) 88 331 (31.1)
Eczema 4015 (9.8) 26 696 (9.4) 8952 (22.0) 59 677 (21.0)
Psoriasis 1059 (2.6) 6856 (2.4) 1696 (4.2) 11 200 (3.9)
Urinary incontinence 1222 (3.0) 7186 (2.5) 3225 (7.9) 18 027 (6.3)
Renal disease or chronic kidney disease 457 (1.1) 3138 (1.1) 5817 (14.3) 37 981 (13.4)
Prostatism 1496 (3.7) 9176 (3.2) 3490 (8.6) 21 464 (7.6)
Cancer 3133 (7.7) 21 956 (7.7) 6307 (15.5) 44 567 (15.7)
History in 12 months before DEP
Any falls 808 (2.0) 4391 (1.6) 808 (2.0) 4391 (1.6)
Any fractures 596 (1.5) 3693 (1.3) 596 (1.5) 3693 (1.3)
Mean (SD) doctor consultations 5.4 (6.3) 4.8 (5.9) 5.4 (6.3) 4.8 (5.9)
*Data missing for 9664 cases and 70 877 controls at the start of the DEP, and 1465 cases and 13 596 controls at the end of the DEP.
†Data missing for 22 940 cases and 159 721 controls at the start of the DEP, and 12 702 cases and 90 129 controls at the end of the DEP.
‡Data missing for 13 086 cases and 94 734 controls at the start of the DEP, and 4736 cases and 37 526 controls at the end of the DEP.
§Since first symptom or diagnosis of depression. 
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1.29) and 1.27 (1.09 to 1.48) respectively. However, for 
antidepressants with an ACB score of 1, the association 
with dementia increased for prescriptions given in 
periods closer to a diagnosis of dementia. Similarly, the 
negative association between gastrointestinal drugs 
and dementia was not seen for exposures 15-20 years 
before the index date.
Supplementary materials, appendix 4 details a 
further analysis of the associations between depression, 
antidepressants, and dementia incidence. Diagnosis 
of depression has no independent association with 
dementia incidence after adjusting for antidepressants 
and other covariates in the model. However, 
antidepressants were consistently associated with 
dementia; this affect was not attenuated by controlling 
for depression, and there was no interaction between 
depression severity and antidepressant drug use with 
respect to dementia incidence.
Sensitivity analyses
Excluding patients with a prescription for a drug 
with an ACB score of 2 or 3 in the 12 months before 
the DEP, hence restricting to new users, resulted in 
5215 cases and 62 161 controls being excluded. This 
led to small reductions in the association between 
dementia incidence and any drug with an ACB score 
of 3 (odds ratio 1.07, 95% confidence interval 1.04 
to 1.10) and any drug with an ACB score of 2 (1.12, 
1.04 to 1.21) adjusted for covariates measured at 
the end of the DEP (see supplementary materials, 
table 3). No substantial changes were seen in 
the association between dementia incidence and 
specific classes of drugs used when restricted to new 
users. In particular, antidepressants and urologicals 
with an ACB score of 3 and antidepressants with an 
ACB score of 1 remained noticeably associated with 
dementia.
Table 2 | Crude and adjusted odds ratios of dementia by prescription of any, defined daily doses (DDDs), and total burden of anticholinergics 
measured with the Anticholinergic Cognitive Burden (ACB) score
Exposure during DEP No of cases (%) No of controls (%)
Odds ratio (95% CI)
Unadjusted Adjusted at start of DEP*† Adjusted at end of DEP*‡
Any use
Prescriptions (ACB score):
 None 4295 (10.5) 36 329 (12.8) 1.00 1.00 1.00
 1 36 437 (89.4) 247 406 (87.1) 1.25§ (1.21 to 1.29) 1.11§ (1.07 to 1.15) 1.10§ (1.06 to 1.15)
 2 1429 (3.5) 7909 (2.8) 1.27§ (1.20 to 1.35) 1.10§ (1.03 to 1.17) 1.10§ (1.03 to 1.16)
 3 14 453 (35.5) 86 403 (30.4) 1.27§ (1.24 to 1.30) 1.16§ (1.13 to 1.19) 1.11§ (1.08 to 1.14)
Number of DDDs (ACB score)
1:
 0 4333 (10.6) 36 527 (12.9) 1.00 1.00 1.00
 >0-13 3000 (7.4) 20 530 (7.2) 1.24§ (1.18 to 1.30) 1.16§ (1.11 to 1.22) 1.14§ (1.08 to 1.20)
 14-89 2530 (6.2) 17 088 (6.0) 1.25§ (1.19 to 1.32) 1.15§ (1.09 to 1.21) 1.13§ (1.07 to 1.19)
 90-364 4253 (10.4) 28 497 (10.0) 1.26§ (1.21 to 1.32) 1.12§ (1.07 to 1.18) 1.09§ (1.04 to 1.15)
 365-1459 8549 (21.0) 56 607 (19.9) 1.28§ (1.23 to 1.33) 1.12§ (1.07 to 1.17) 1.10§ (1.05 to 1.15)
 >1460 18 105 (44.4) 124 684 (43.9) 1.23§ (1.19 to 1.28) 1.05 (1.01 to 1.10) 1.05 (1.01 to 1.10)
2:
 0 39 341 (96.5) 276 024 (97.2) 1.00 1.00 1.00
 >0-13 704 (1.7) 4301 (1.5) 1.15§ (1.06 to 1.25) 1.01 (0.93 to 1.10) 1.02 (0.94 to 1.11)
 14-89 266 (0.7) 1533 (0.5) 1.22§ (1.07 to 1.39) 1.08 (0.94 to 1.23) 1.07 (0.94 to 1.23)
 90-364 218 (0.5) 1035 (0.4) 1.48§ (1.28 to 1.72) 1.23§ (1.06 to 1.43) 1.20 (1.03 to 1.40)
 365-1459 176 (0.4) 826 (0.3) 1.50§ (1.27 to 1.76) 1.23 (1.04 to 1.45) 1.18 (0.99 to 1.39)
 >1460 65 (0.2) 214 (0.1) 2.15§ (1.63 to 2.83) 1.62§ (1.22 to 2.15) 1.57§ (1.18 to 2.09)
3:
 0 26 317 (64.5) 197 530 (69.6) 1.00 1.00 1.00
 >0-13 5663 (13.9) 38 084 (13.4) 1.13§ (1.10 to 1.17) 1.07§ (1.04 to 1.11) 1.04 (1.01 to 1.08)
 14-89 2440 (6.0) 15 154 (5.3) 1.23§ (1.17 to 1.28) 1.13§ (1.08 to 1.18) 1.07§ (1.02 to 1.12)
 90-364 2786 (6.8) 15 462 (5.4) 1.37§ (1.31 to 1.43) 1.24§ (1.19 to 1.30) 1.17§ (1.12 to 1.22)
 365-1459 2512 (6.2) 12 626 (4.4) 1.51§ (1.45 to 1.58) 1.35§ (1.29 to 1.42) 1.27§ (1.21 to 1.33)
 >1460 1052 (2.6) 5077 (1.8) 1.59§ (1.49 to 1.71) 1.40§ (1.30 to 1.50) 1.31§ (1.22 to 1.41)
Average ACB score
<0.1 9517 (23.3) 74 445 (26.2) 1.00 1.00 1.00
0.1-0.4 6084 (14.9) 41 528 (14.6) 1.15§ (1.11 to 1.19) 1.09§ (1.05 to 1.13) 1.07§ (1.03 to 1.11)
0.5-0.9 5781 (14.2) 40 413 (14.2) 1.12§ (1.08 to 1.16) 1.06§ (1.02 to 1.10) 1.06§ (1.02 to 1.10)
1.0-1.9 9030 (22.2) 62 348 (22.0) 1.14§ (1.10 to 1.17) 1.06§ (1.03 to 1.10) 1.07§ (1.01 to 1.09)
2.0-2.9 4914 (12.1) 33 113 (11.7) 1.17§ (1.13 to 1.21) 1.07§ (1.03 to 1.12) 1.07§ (1.02 to 1.12)
3.0-4.9 3874 (9.5) 23 954 (8.4) 1.28§ (1.23 to 1.33) 1.13§ (1.08 to 1.19) 1.12§ (1.07 to 1.18)
>5.0 1570 (3.9) 8132 (2.9) 1.53§ (1.44 to 1.62) 1.31§ (1.23 to 1.40) 1.28§ (1.19 to 1.36)
DEP=drug exposure period
*Adjusted for age, region, any falls, any fractures, and number of doctor consultations in the 12 months before the DEP. Also adjusted for the number of prescriptions during the DEP for the 
following drugs not rated as anticholinergic: benzodiazepines, z drugs, antidepressants, antinausea and antivertigo preparations, antiepileptics, and antiparkinson drugs.
†Adjusted for the following variables measured at the start of the DEP: body mass index, smoking status, harmful alcohol use, depression duration (0, 0-2, 2-5, 5-10, 10-20, and >20 years), and 
all diagnoses listed in table 1.
‡Adjusted for the following variables measured at the end of the DEP: body mass index, smoking status, harmful alcohol use, depression duration (0, 0-5, 5-10, 10-15, 15-20, and >20 years), 
and all diagnoses listed in table 1.
§P<0.01.
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Findings remained similar when also analysed by 
more than 90 DDDs of exposure versus less, rather 
than any prescription versus none (results not shown).
Although there were differences in the number of 
drugs with an ACB score of 1 and 2 and drugs with 
an Anticholinergic Drug Scale (ADS) score of 1 and 
2, the proportion of patients with a prescription for 
drugs with an ACB or ADS score of 3 were similar 
(see supplementary materials, table 4). There was 
good concordance between drugs with an ACB or 
ADS score of 3 (Cohen’s kappa 0.91). Prescription of 
any drugs with an ADS score of 3 had a marginally 
lower association with dementia (odds ratio 1.08, 
95% confidence interval 1.06 to 1.11) adjusted for 
covariates at the end of the DEP, than drugs with an 
ACB score of 3 (1.11, 1.08 to 1.14). However, when 
analysed by the drug class, the findings were very 
similar with the antidepressant, antiparkinson, 
and urological drugs with an ADS score of 3 and 
antidepressants with an ADS score of 1 consistently 
associated with greater dementia incidence (data 
not shown), but no association with other ADS 
classes.
Missing data
There were relatively high proportions of missing 
data for the body mass index, smoking, and alcohol 
variables. There was very little difference in any 
results when comparing estimates with and without 
adjustment for these variables among the main dataset 
and those with complete data (see supplementary 
materials, table 5), suggesting that our findings are not 
sensitive to missing data in these covariates.
discussion
In this case-control study of older adults in the UK, 
there was a noticeable association between increasing 
total anticholinergic burden over the previous 4-20 
years and incident dementia diagnosis. However, this 
dose-response effect was not seen for cumulative use 
of drugs with an Anticholinergic Cognitive Burden 
(ACB) score of 1 (possibly anticholinergic), and was 
only evident for certain classes of anticholinergic 
drugs. Antidepressants (predominantly amitriptyline, 
dosulepin, and paroxetine) and urologicals 
(predominantly oxybutynin and tolterodine) with 
an ABC score of 3 (definitely anticholinergic) were 
consistently associated with incident dementia. These 
relations were seen even for exposures 15-20 years 
before the diagnosis of dementia, suggesting that 
reverse causation or confounding with early dementia 
symptoms are less likely explanations for the effect. 
Prescription of gastrointestinal drugs with an ACB score 
of 3 was not positively associated with dementia in any 
of our analyses. Other antidepressants (predominantly 
selective serotonin reuptake inhibitors) with an ACB 
score of 1 were associated with dementia, but that 
association was greater for prescriptions close to 
Table 3 | Adjusted odds ratios of dementia by prescription of an anticholinergic drug by Anticholinergic Cognitive 
Burden (ACB) score and drug class
Drug class No of cases (%) No of controls (%)
Odds ratio (95% CI)
Adjusted at start of DEP*† Adjusted at end of DEP*‡
ACB score of 1
Analgesic 23 871 (58.6) 158 162 (55.7) 1.02 (1.00 to 1.05) 1.02 (0.99 to 1.04)
Antidepressant 5958 (14.6) 28 767 (10.1) 1.37§ (1.32 to 1.42) 1.25§ (1.20 to 1.30)
Antipsychotic 8051 (19.7) 50 079 (17.6) 1.05§ (1.02 to 1.08) 1.04 (1.01 to 1.07)
Cardiovascular 27 926 (68.5) 191 895 (67.6) 0.97 (0.94 to 0.99) 0.98 (0.95 to 1.01)
Gastrointestinal 10 845 (26.6) 71 814 (25.3) 0.97 (0.94 to 0.99) 0.96§ (0.93 to 0.99)
Respiratory 9385 (23.0) 62 787 (22.1) 0.99 (0.97 to 1.02) 0.99 (0.97 to 1.02)
Other 11 521 (28.3) 77 345 (27.2) 0.95§ (0.92 to 0.97) 0.95§ (0.92 to 0.98)
ACB score of 2
Analgesic 385 (0.9) 2337 (0.8) 1.03 (0.92 to 1.15) 1.03 (0.92 to 1.16)
Antipsychotic 22 (0.1) 69 (0.0) 1.44 (0.87 to 2.36) 1.35 (0.82 to 2.23)
Antiparkinson 57 (0.1) 141 (0.0) 1.55§ (1.12 to 2.14) 1.32 (0.96 to 1.82)
Respiratory 19 (0.0) 123 (0.0) 0.89 (0.55 to 1.45) 0.83 (0.51 to 1.36)
Other 985 (2.4) 5454 (1.9) 1.07 (1.00 to 1.15) 1.09 (1.01 to 1.17)
ACB score of 3
Antidepressant 8823 (21.6) 50 817 (17.9) 1.13§ (1.10 to 1.16) 1.11§ (1.08 to 1.14)
Antipsychotic 1036 (2.5) 5140 (1.8) 1.09 (1.02 to 1.18) 1.07 (1.00 to 1.16)
Gastrointestinal 1817 (4.5) 12 057 (4.2) 0.94 (0.89 to 0.99) 0.94 (0.89 to 0.99)
Antiparkinson 270 (0.7) 951 (0.3) 1.45§ (1.25 to 1.68) 1.29§ (1.11 to 1.50)
Respiratory 4002 (9.8) 25 195 (8.9) 1.04 (1.00 to 1.08) 1.03 (1.00 to 1.07)
Urological 3261 (8.0) 16 873 (5.9) 1.23§ (1.18 to 1.28) 1.18§ (1.13 to 1.23)
Other 284 (0.7) 1741 (0.6) 0.99 (0.87 to 1.13) 0.99 (0.87 to 1.13)
DEP=drug exposure period
*Adjusted for age, region, any falls, any fractures, and number of doctor consultations in the 12 months before the DEP. Also adjusted for the number of 
prescriptions during the DEP for the following drugs not rated as anticholinergic: benzodiazepines, z drugs, antidepressants, antinausea and antivertigo 
preparations, antiepileptics, and antiparkinson drugs.
†Adjusted for the following variables measured at the start of the DEP: body mass index, smoking status, harmful alcohol use, depression duration  
(0, 0-2, 2-5, 5-10, 10-20, and >20 years), and all diagnoses listed in table 1.
‡Adjusted for the following variables measured at the end of the DEP: body mass index, smoking status, harmful alcohol use, depression duration  
(0, 0-5, 5-10, 10-15, 15-20, and >20 years), and all diagnoses listed in table 1.
§P<0.01.
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dementia incidence, suggesting that reverse causation 
could be a possible explanation for this observed 
association. Other drugs with an ACB score of 1 were 
not associated with increased dementia incidence.
Strengths and weaknesses of the study
This is the first study to individually estimate the effect 
of classes of anticholinergic drugs with respect to 
dementia incidence. Our study used a large, population 
Table 4 | Adjusted odds ratios (OR) of dementia by prescription of anticholinergic drugs, by drug class, and by period before a diagnosis of dementia
Drug class
Exposure period (years before index date)
15-20* 10-15† 4-10‡
No of cases 
(n=10 684)
No of controls 
(n=74 145)
OR§ (95% 
CI)
No of cases 
(n=23 959)
No of controls 
(n=166 735) OR§ (95% CI)
No of cases 
(n=40 770)
No of controls 
(n=283 933) OR§ (95% CI)
Any use
Prescriptions  
(ACB score):
  None 3638 27 905 1.00 5602 44 790 1.00 4492 38 579 1.00
  1 6789 44 564 1.05 (1.00 
to 1.10)
17 867 118 973 1.06¶ (1.02 
to 1.10)
35 722 242 210 1.06¶ (1.02 
to 1.09)
  2 193 1057 1.07 (0.91 
to 1.25)
493 2556 1.14¶ (1.03 
to 1.26)
1054 5734 1.11¶ (1.03 
to 1.18)
  3 1972 11 321 1.17¶ (1.10 
to 1.24)
5242 30 303 1.15¶ (1.10 
to 1.19)
12 338 72 335 1.13¶ (1.10 
to 1.15)
Any use by drug class
Prescriptions  
(ACB score):
  None 3638 27 905 1.00 5602 44 790 1.00 4492 38 579 1.00
  1:
   Analgesic 3638 22 914 1.06 (1.01 
to 1.11)
9771 62 234 1.05¶ (1.02 
to 1.08)
21 756 143 993 0.99 (0.96 to 
1.01)
   Antidepressant 262 1429 1.08 (0.93 
to 1.24)
3813 24 345 1.18¶ (1.11 
to 1.26)
5413 25 566 1.37¶ (1.32 
to 1.42)
   Antipsychotic 932 6032 0.99 (0.92 
to 1.07)
2507 15 429 1.04 (0.99 to 
1.09)
6392 39 642 1.03 (1.00 to 
1.07)
   Cardiovascular 3672 23 851 1.02 (0.97 
to 1.08)
11 785 79 119 0.99 (0.95 to 
1.02)
27 256 187 816 0.95¶ (0.92 
to 0.97)
   Gastrointestinal 1863 12 023 0.97 (0.92 
to 1.03)
4447 28 709 0.98 (0.94 to 
1.02)
8404 55 944 0.95¶ (0.92 
to 0.98)
   Respiratory 990 6658 0.96 (0.89 
to 1.04)
2913 18 767 1.01 (0.97 to 
1.06)
7784 52 560 0.98 (0.95 to 
1.01)
   Other 1230 8230 0.94 (0.88 
to 1.02)
1396 7091 0.98 (0.94 to 
1.02)
9792 66 244 0.91¶ (0.89 
to 0.94)
  2:
   Analgesic 64 358 1.09 (0.83 
to 1.43)
102 654 0.92 (0.75 to 
1.14)
254 1518 1.05 (0.91 to 
1.20)
   Antipsychotic 8 16 NA 10 28 NA 14 48 NA
   Antiparkinson <5 12 NA 17 22 NA 47 116 1.59 (1.11 to 
2.28)
   Respiratory <5 26 NA 8 35 NA 12 75 NA
   Other 120 675 0.99 (0.80 
to 1.21)
363 1873 1.12 (1.00 to 
1.26)
745 4056 1.07 (0.99 to 
1.17)
  3:
   Antidepressant 1155 6302 1.19¶ (1.10 
to 1.29)
3237 17 828 1.16¶ (1.11 
to 1.22)
7342 41 826 1.12¶ (1.08 
to 1.15)
   Antipsychotic 189 952 1.2 (1.00 to 
1.42)
377 2024 0.98 (0.86 to 
1.10)
781 3679 1.14¶ (1.04 
to 1.23)
   Gastrointestinal 273 1568 1.11 (0.97 
to 1.28)
522 3453 0.93 (0.84 to 
1.02)
1283 8721 0.91¶ (0.85 
to 0.97)
   Antiparkinson 29 146 1.29 (0.83 
to 2.01)
104 379 1.54¶ (1.22 
to 1.96)
230 786 1.56¶ (1.33 
to 1.83)
   Respiratory 524 3247 1.07 (0.97 
to 1.18)
1228 7615 1.04 (0.97 to 
1.10)
2839 17 807 1.03 (0.99 to 
1.08)
   Urological 207 995 1.27¶ (1.09 
to 1.48)
810 4139 1.22¶ (1.13 
to 1.32)
2870 14 654 1.23¶ (1.18 
to 1.29)
   Other 43 281 0.97 (0.70 
to 1.34)
93 569 0.97 (0.78 to 
1.21)
176 1051 1.02 (0.86 to 
1.20)
ACB=Anticholinergic Cognitive Burden
*Including patients with ≥16 years of up to standard (UTS) data history before the index date.
†Including patients with ≥11 years of UTS data history before the index date.
‡Including patients with ≥6 years of UTS data history before the index date.
§Adjusted for age, region, number of prescriptions during the drug exposure period (DEP) for the following drugs not rated as anticholinergic: benzodiazepines, z drugs, antidepressants, 
antinausea and antivertigo preparations, antiepileptics, and antiparkinsons drugs. Also adjusted for the following variables measured at the start of the DEP: any falls, any fractures and number of 
doctor consultations in the 12 months before the DEP; body mass index; smoking status; harmful alcohol use; depression duration (0, 0-2, 2-5, 5-10, 10-20, and >20 years); and all diagnoses 
listed in table 1.
¶P<0.01.
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representative, primary care database that allowed a 
detailed analysis of the association between dementia 
incidence and prescriptions of different drugs classes 
up to 20 years before a diagnosis of dementia. However, 
there are several limitations to our approach.
In the UK, most diagnoses of dementia are made 
by memory services specialists. The diagnoses are 
then communicated back to primary care. Therefore, 
our cases are likely to represent genuine cases of 
dementia. Dementia codes in the Clinical Practice 
Research Datalink (CPRD) reflect diagnoses well with a 
positive predictive value of 95%.23 However, dementia 
is known to be under diagnosed, with up to 50% of 
people with dementia undiagnosed at any time.34 
Hence it is possible that some of our controls have 
undiagnosed dementia or early cognitive impairment. 
This misclassification would shrink estimated effects 
towards the null (odds ratio of 1) but would not remove 
them completely. It is possible that surveillance bias 
influences the findings in that the patients who are 
prescribed anticholinergic drugs may be more likely to 
be diagnosed with dementia owing to their increased 
contact with health services. However, this effect 
would be observed across all drug classes and so is 
unlikely to account for our findings.
It is difficult to accurately assess the anticholinergic 
activity of each drug, and anticholinergic scales differ 
with respect to how they classify drugs.29 However, 
there was good agreement between the Anticholinergic 
Drug Scale (ADS) and the ACB scale. Our findings were 
the same when using each scale. We do not know 
whether patients adhered to their prescribed drugs. 
Drugs obtained over-the-counter are not recorded in 
our data, hence we will have likely underestimated 
the use of certain antihistamines. Defined daily doses 
(DDDs) can be difficult to establish for certain drugs 
yet represent the best available method for comparing 
the levels of exposure of different drug classes. Our 
findings did not change when we instead analysed the 
number of prescriptions to quantify exposure (results 
not shown). DDDs also do not capture the relative 
anticholinergic activity across classes. Commonly 
used scales including the ACB scale typically assume 
that drugs with a score of 3 have three times the 
anticholinergic activity of those with a score of 1, 
but this is difficult to justify. Hence we stratified our 
results by drugs with an ACB score of 1, 2, or 3 in 
primary analysis to not enforce any particular relative 
anticholinergic activity, and separated by drug classes 
within those groups to avoid directly comparing DDDs 
across groups.
As in any observational study, unmeasured 
or residual confounding could underlie positive 
associations, and many causes of dementia are 
unknown. Primary care records do not hold detailed 
lifestyle or demographic information, but do include 
detailed records of diagnoses and symptoms that 
have allowed good confounding control. With 
respect to study design, our estimates generalise to 
those surviving at least four years after their initial 
anticholinergic exposure, and the nested case control 
design provides unbiased estimates of effects when 
compared with the equivalent cohort study.35
Strengths and weaknesses in relation to other 
studies
Many studies have linked anticholinergic drug use 
with concurrent or short term cognitive effects, 
but few have examined associations of long term 
anticholinergic exposure;8 the latter tend to report 
positive associations.12-15 Our findings are consistent 
with these studies, particularly a US cohort study of 
3434 participants monitored over an average of seven 
years.12 Anticholinergic antidepressants were linked 
to dementia incidence, consistent with our results, 
however, the authors did not test specific classes of the 
remaining anticholinergics. A US case-control study 
of 141 940 nursing home residents with depression 
found a greater adjusted odds ratio of 1.24 (95% 
confidence interval 1.20 to 1.28) for anticholinergic 
drugs use in the 90 days before a diagnosis of dementia 
based on administrative data.15
Our study uses a longer patient history in a larger 
sample of patients. This enables a much more granular 
disaggregation of the effects of specific drug classes in 
different periods before diagnosis, and in the depth of 
confounding control possible using complete primary 
care records, which enables exploration of alternative 
explanations for observed associations. Together these 
aspects substantially narrow the target of potential 
harm. Although set in the UK, our findings are likely 
generalisable to other developed countries.
Implications for clinicians and policymakers
The associations reported here are moderate (odds 
ratios for different exposures between 1.1 and 1.3), but 
given the high incidence of dementia they reflect an 
appreciable risk to patients. For example, the odds ratio 
for dementia associated with any use of antidepressants 
with an ACB score of 3 15-20 years before the index 
date is 1.19 (95% confidence interval 1.10 to 1.29). 
A typical patient aged 65-70 might normally expect a 
period incidence of dementia of around 10% over the 
next 15 years,36 so this odds ratio would be consistent 
with an absolute risk increase of 2% (1% to 3%) over 
that period, corresponding to a number needed to 
harm of 50 (33 to 100). Possible explanations for our 
findings are that other actions of specific groups of 
anticholinergic drugs may underlie observed effects, or 
that the drugs are markers of prodromal symptoms or 
dementia risk factors. Alternatively, the class specific 
association we have observed may reflect a difference 
in the ability of different groups of anticholinergics to 
cross the blood-brain barrier.
Mechanistic evidence for a link between 
anticholinergic drugs and dementia incidence is 
limited, but neuropathological studies in humans and 
mice do support a role of anticholinergics affecting 
neurodegenerative pathology.37 38 Most recently, 
a cross sectional analysis of Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) and Indiana Memory 
and Ageing Study (IMAS) data linked anticholinergic 
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drug use to reduced glucose metabolism and increased 
brain atrophy, and to future mild cognitive impairment 
or Alzheimer’s disease incidence among cognitively 
normal participants (hazard ratio 2.47, P=0.01).39 
This study did not disaggregate subclasses of drugs. 
Evidence from anticholinergic cessation trials have not 
shown improvements in cognitive function, but these 
have been underpowered and focused on short term 
outcomes.40
Anticholinergic urological drugs, particularly 
oxybutynin, have been consistently associated with 
short term cognitive decline in randomised controlled 
trials,8 41 so a long term risk of dementia is plausible. 
Lower urinary tract symptoms themselves have been 
linked to future dementia incidence and may be a 
symptom of early neurodegeneration.42 43 To account 
for our finding, urinary incontinence would need to be 
a substantial risk factor for dementia diagnosed 15-20 
years later.
Antidepressants (mainly selective serotonin 
reuptake inhibitors) with an ACB score of 1 were 
only associated with dementia close to the time of 
prescription. Conversely the finding of a constant 
association between dementia and antidepressants 
with an ACB score of 3 across the 20 years before 
dementia incidence, is more likely to represent 
a causal link. Although we carefully adjusted for 
depression diagnosis, severity, symptoms, and 
duration (see supplementary materials, appendix 4), 
residual confounding cannot be excluded. Depression 
has consistently been shown to be linked to increased 
dementia incidence in the short to medium term (up 
to 10 years). However, studies with longer follow-up 
periods have often failed to detect an association, or 
have reported weaker associations, between midlife 
depression and dementia in later life.1 20 This suggests 
that residual confounding is unlikely to account for our 
observed association between antidepressants with an 
ACB score of 3 and dementia.
Patients with Parkinson’s disease have an elevated 
risk of dementia;44 anticholinergic antiparkinson drugs 
have previously been associated with greater cognitive 
decline.45 This study provides further evidence that 
anticholinergic drugs should be avoided when treating 
patients with Parkinson’s disease.
In each case (antidepressants, antiparkinsons, and 
urologicals with an ACB score of 3) a dose-response 
effect is seen with a smaller, but noticeable, positive 
association between dementia and recorded use of less 
than 90 DDDs (see supplementary materials, table 2). 
It is possible that in some cases these low exposures 
reflect a longer exposure that is not captured in the 
patients’ current primary care record.
Previous research linking all anticholinergics 
to dementia incidence may have dissuaded some 
patients and clinicians from the use of anticholinergic 
antihistamine, cardiovascular, or gastrointestinal 
drugs. We find a slight negative association between 
gastrointenstinal drugs with an ACB score of 1 and 
3 and dementia with an apparent dose-response 
effect, although there is no mechanistic explanation 
for this. Cardiovascular drugs with an ACB score of 1 
were also negatively associated with dementia with 
prolonged exposure (odds ratio 0.95, 95% confidence 
interval 0.91 to 0.99; supplementary materials, table 
2), suggesting their protective effect outweighs any 
possible harm associated with their anticholinergic 
properties. A small association between antihistamine 
use and dementia was observed that did not meet 
our threshold for statistical significance. Although 
very few patients (around 0.3% of the sample) are 
prescribed more than 365 DDDs of antihistamines 
in our study, those with fewer prescriptions may also 
have a substantial over-the-counter use that is not 
recorded. Patients who are prescribed more than 365 
DDDs may comprise a lower socioeconomic status 
group for whom prescribed drugs are free of charge, 
hence preferred to over-the-counter drugs. Our 
results, although in need of independent confirmation 
particularly for antihistamines, should reassure 
these patients. Nevertheless, we do not dispute the 
possible short term harms of all anticholinergic drugs 
used among vulnerable groups, including short term 
cognitive impairment, and would advocate current 
guidance of vigilant use or avoidance among frail older 
people.
Considerations for future research
Adjusting for time varying confounders is difficult 
in a matched case-control study.31 46 We measured 
covariates at the start and end of the drug exposure 
period (DEP). Since there was little difference between 
these estimates in most cases we are confident that the 
effect of time varying covariates does not considerably 
affect our findings. Secondly, to be certain that 
potential confounders preceded drug initiation and 
not vice versa, we further excluded patients who 
were prevalent users at the start of each DEP, again 
with little difference in results. We suggest that 
authors undertaking case-control studies comparing 
cumulative exposure over a long period carefully 
consider how time varying covariates and exposure 
before the period in which they are being directly 
measured might affect study findings. Future research 
into the potential harms of anticholinergics must 
consider differential effects of individual drug classes 
and their potentially different mechanisms of action. 
Carefully conducted prospective studies in specific 
cohorts of patients comparing the long term cognitive 
effects and neuropathological correlates of specific 
drug classes are needed.
Conclusion
Many people use anticholinergic drugs at some point in 
their lives, and many are prescribed to manage chronic 
conditions leading to potentially long exposures. 
There are robust associations between levels of 
anticholinergic antidepressants, antiparkinsons, and 
urologicals and the risk of a diagnosis of dementia 
up to 20 years after exposure. Other anticholinergics 
appear not to be linked to the risk of dementia, and 
risks remain uncertain for other drugs. Clinicians 
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should continue to be vigilant with respect to the use 
of anticholinergic drugs, and should consider the risk 
of long term cognitive effects, as well as short term 
effects, associated with specific drug classes when 
performing their risk-benefit analysis.
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